Voyager Therapeutics (VYGR) Cash from Operations (2014 - 2026)
Voyager Therapeutics (VYGR) posted Cash from Operations of 33419000.0 for Q1 2026, down 10.43% sequentially from 30263000.0 in Q4 2025, and up 11.81% YoY from 29888673.98 in Q1 2025.
Voyager Therapeutics (VYGR) Cash from Operations (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Cash from Operations for 13 years, with the latest figure at 33419000.0 in Q1 2026.
- Quarterly Cash from Operations rose 11.81% year-over-year to 33419000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 127991000.0 (down 14.31% YoY) and the FY2025 annual result came in at 132467000.0, down 765.23% from the prior year.
- Cash from Operations slipped to 33419000.0 in Q1 2026 per VYGR's latest filing, from 30263000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 123565000.0 in Q1 2023 and troughed at 37895000.0 in Q1 2025.
- A 5-year average of 6810941.18 and a median of 21051000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations soared 261.67% in 2022, then tumbled 3682.04% in 2024.
- Over 5 years, Cash from Operations stood at 12244000.0 in 2022, then sank by 94.05% to 23760000.0 in 2023, then soared by 38.85% to 14529000.0 in 2024, then slumped by 108.29% to 30263000.0 in 2025, then retreated by 10.43% to 33419000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 33419000.0, 30263000.0, and 31048000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Voyager Therapeutics | 205.86 Mn | 89.52 Mn | - | -25.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.84 Mn |
| Jun 30, 2026 | -25.84 Mn |
| Mar 31, 2026 | -33.42 Mn |
| Mar 31, 2026 | -33.42 Mn |
| Dec 31, 2025 | -30.26 Mn |
| Dec 31, 2025 | -30.26 Mn |
| Sep 30, 2025 | -31.05 Mn |
| Sep 30, 2025 | -31.05 Mn |
| Jun 30, 2025 | -33.26 Mn |
| Jun 30, 2025 | -33.26 Mn |
| Mar 31, 2025 | -37.90 Mn |
| Mar 31, 2025 | -37.90 Mn |
| Dec 31, 2024 | -14.53 Mn |
| Dec 31, 2024 | -14.53 Mn |
| Sep 30, 2024 | -27.97 Mn |
| Sep 30, 2024 | -27.97 Mn |
| Jun 30, 2024 | -31.58 Mn |
| Jun 30, 2024 | -31.58 Mn |
| Mar 31, 2024 | 58.77 Mn |
| Mar 31, 2024 | 58.77 Mn |